# ADAPTcycle (NCT04055493)

> Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04055493
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Women's Cancer Study Group GmbH
- Conditions: Breast Cancer Female
- Interventions: Ribociclib 200Mg Oral Tablet
- Enrollment: 1684
- Primary outcome: invasive disease-free survival (iDFS)
- Primary outcome: distant disease-free survival (dDFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 14
- X threads: 9
- Podcasts: 7

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=adaptcycle-nct04055493

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04055493", "email": "<work email>"}; the inbox owner confirms by the emailed link.